Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus.

NCT02794285 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02794285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02794285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus.
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2016
Completion date
December 21, 2021
Enrollment
559 (actual)
Sites
175

Conditions

As the registry lists them; a condition with its own page is linked.

active systemic lupus erythematosus